Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1179 results:

  • 1. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
    Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
    J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Complete remission in a pretreated, microsatellite-stable,
    He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
    Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-pd-1 antibodies in combination with radiotherapy.
    Chen JY; Lin PY; Hong WZ; Yang PC; Chiang SF; Chang HY; Ke TW; Liang JA; Chen WT; Chao KSC; Huang KC
    Cancer Immunol Immunother; 2024 Apr; 73(5):92. PubMed ID: 38564022
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring the clinical significance of IL-38 correlation with pd-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
    Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
    Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Precursor exhausted CD8
    Huang H; Ge J; Fang Z; Wu S; Jiang H; Lang Y; Chen J; Xiao W; Xu B; Liu Y; Chen L; Zheng X; Jiang J
    Front Immunol; 2024; 15():1362140. PubMed ID: 38510246
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Serum iron element: A novel biomarker for predicting pd-1 immunotherapy efficacy.
    Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
    Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Long-Term Outcomes of dMMR/MSI-H Rectal cancer Treated With Anti-pd-1-Based Immunotherapy as Curative-Intent Treatment.
    Yu JH; Liao LE; Xiao BY; Zhang X; Wu AW; Cheng Y; Tang JH; Jiang W; Kong LH; Han K; Mei WJ; Hong ZG; Yang WJ; Li DD; Pan ZZ; Li YF; Zhang XS; Ding PR
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38498975
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Intratumoral injection of interferon gamma promotes the efficacy of anti-pd1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
    Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
    Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Efficacy and safety of pd-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
    Yang Z; Gao J; Zheng J; Han J; Li A; Liu G; Sun Y; Zhang J; Chen G; Xu R; Zhang X; Liu Y; Bai Z; Deng W; He W; Yao H; Zhang Z
    Signal Transduct Target Ther; 2024 Mar; 9(1):56. PubMed ID: 38462629
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
    Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Association of preoperative aspartate aminotransferase to platelet ratio index with outcomes and tumour microenvironment among colorectal cancer with liver metastases.
    Chen Q; Deng Y; Li Y; Chen J; Zhang R; Yang L; Guo R; Xing B; Ding P; Cai J; Zhao H
    Cancer Lett; 2024 Apr; 588():216778. PubMed ID: 38458593
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
    Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
    Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Sirtuin 2 up-regulation suppresses the anti-tumour activity of exhausted natural killer cells in mesenteric lymph nodes in murine colorectal carcinoma.
    Jiang B; Ke C; Zhou H; Xia T; Xie X; Xu H
    Scand J Immunol; 2023 Nov; 98(5):e13317. PubMed ID: 38441393
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-pd-1 therapy efficacy against colorectal cancer.
    Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
    Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Phenotypic and functional exhaustion of circulating CD3
    Cao K; Wang X; Wang H; Xu C; Ma A; Zhang Y; Zheng M; Xu Y; Tang L
    FASEB J; 2024 Mar; 38(5):e23525. PubMed ID: 38430373
    [TBL] [Abstract] [Full Text] [Related]  


    of 59.